{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:50:31Z","timestamp":1791409831557,"version":"4.3.3"},"reference-count":97,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["Postgraduate Support Grant Call 3 (Project No. 50880)"],"award-info":[{"award-number":["Postgraduate Support Grant Call 3 (Project No. 50880)"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017057","name":"Egypt Ministry of Higher Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.bioorg.2026.110313","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T23:00:48Z","timestamp":1785538848000},"page":"110313","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Ligand-based design and synthesis of novel 3-spiro-2-oxindoline derivatives as potent VEGFR-2 inhibitors with antiproliferative activity and cell cycle arrest"],"prefix":"10.1016","volume":"181","author":[{"given":"Islam R.","family":"Sweify","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend A.A.","family":"Abd El-Wahab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesam S.","family":"Qayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine","family":"Hosny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael M.","family":"El-Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Rog\u00e9rio A.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Aboul-Fadl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0005","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/clinchem\/hvad202","article-title":"Epidemiology of Cancer","volume":"70","author":"Schwartz","year":"2024","journal-title":"Clin. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110313_bb0010","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1353\/pbm.2019.0046","article-title":"What is Cancer?","volume":"62","author":"Hausman","year":"2019","journal-title":"Perspect. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110313_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116472","article-title":"Recent advances and future directions on small molecule VEGFR inhibitors in oncological conditions","volume":"272","author":"Thakur","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2026.110313_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12040827","article-title":"Decoding tumor angiogenesis for therapeutic advancements: mechanistic insights","volume":"12","author":"Kaur","year":"2024","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110313_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70313","article-title":"Angiogenesis and targeted therapy in the tumour microenvironment: from basic to clinical practice","volume":"15","author":"Yang","year":"2025","journal-title":"Clin. Transl. Med."},{"issue":"45","key":"10.1016\/j.bioorg.2026.110313_bb0030","doi-asserted-by":"crossref","first-page":"33384","DOI":"10.1039\/D4RA05244G","article-title":"Recent updates on potential of VEGFR-2 small-molecule inhibitors as anticancer agents","volume":"14","author":"Chaudhari","year":"2024","journal-title":"RSC Adv."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110313_bb0035","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1080\/1061186X.2025.2508985","article-title":"Revisiting VEGF\/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?","volume":"33","author":"Yao","year":"2025","journal-title":"J. Drug Target."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110313_bb0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12272-025-01545-1","article-title":"Targeting vascular endothelial growth receptor-2 (VEGFR-2): structural biology, functional insights, and therapeutic resistance","volume":"48","author":"Shah","year":"2025","journal-title":"Arch. Pharm. Res."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110313_bb0045","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2008.12.011","article-title":"Angiogenesis in liver disease","volume":"50","author":"Fern\u00e1ndez","year":"2009","journal-title":"J. Hepatol."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110313_bb0050","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1365-2362.2007.01866.x","article-title":"Activated VEGFR2\/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer","volume":"37","author":"Giatromanolaki","year":"2007","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.bioorg.2026.110313_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116097","article-title":"Design and synthesis of novel (S)-naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro\/in vivo breast cancer models","volume":"37","author":"Han","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0060","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1186\/s12967-024-05893-2","article-title":"Discovery of novel VEGFR2 inhibitors against non-small cell lung cancer based on fingerprint-enhanced graph attention convolutional network","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.bioorg.2026.110313_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102224","article-title":"Recent advancements of antiangiogenic combination therapies in ovarian cancer","volume":"98","author":"An","year":"2021","journal-title":"Cancer Treat. Rev."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110313_bb0070","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1002\/cncr.34493","article-title":"Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: updated results from the phase 3 COSMIC-311 trial","volume":"128","author":"Brose","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.bioorg.2026.110313_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112752","article-title":"Novel 2-indolinone thiazole hybrids as sunitinib analogues: design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity","volume":"208","author":"Mahmoud","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110313_bb0085","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1634\/theoncologist.2009-0317","article-title":"Bevacizumab","volume":"15","author":"Kazazi-Hyseni","year":"2010","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.bioorg.2026.110313_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179202","article-title":"Gastrointestinal cancer cells treatment with bevacizumab activates a VEGF autoregulatory mechanism involving telomerase catalytic subunit hTERT via PI3K-AKT, HIF-1\u03b1 and VEGF receptors","volume":"12","author":"Mahfouz","year":"2017","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0095","doi-asserted-by":"crossref","DOI":"10.1038\/srep24460","article-title":"Discovery of potent VEGFR-2 inhibitors based on furopyrimidine and thienopyrimidne scaffolds as cancer targeting agents","volume":"6","author":"Aziz","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110313_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ph15111416","article-title":"Design, synthesis, molecular modeling, and anticancer evaluation of new VEGFR-2 inhibitors based on the indolin-2-one scaffold","volume":"15","author":"Abdelgawad","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-022-01310-7","article-title":"Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy","volume":"15","author":"Liu","year":"2022","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0110","doi-asserted-by":"crossref","first-page":"9776","DOI":"10.1021\/acs.jmedchem.3c01629","article-title":"Overcoming secondary mutations of type II kinase inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0115","doi-asserted-by":"crossref","first-page":"5712","DOI":"10.1080\/07391102.2021.1872417","article-title":"Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: binding site analysis of type II, \u2018DFG-out\u2019 inhibitors","volume":"40","author":"Modi","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"8","key":"10.1016\/j.bioorg.2026.110313_bb0120","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/ddr.22109","article-title":"Design, synthesis, and antitumor screening of new thiazole, thiazolopyrimidine, and thiazolotriazine derivatives as potent inhibitors of VEGFR-2","volume":"84","author":"Abd Elhameed","year":"2023","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2026.110313_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104532","article-title":"Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma","volume":"107","author":"Eissa","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0130","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2019.02.050","article-title":"Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors","volume":"168","author":"Zeidan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0135","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110313_bb0140","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2147\/DDDT.S443107","article-title":"Understanding sorafenib-induced cardiovascular toxicity: mechanisms and treatment implications","volume":"18","author":"Li","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.bioorg.2026.110313_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107975","article-title":"Structure activity relationship for anticancer activities of spirooxindole derivatives: a comprehensive review","volume":"154","author":"Pradhan","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110313_bb0150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1080\/17460441.2020.1733526","article-title":"An overview of spirooxindole as a promising scaffold for novel drug discovery","volume":"15","author":"Zhou","year":"2020","journal-title":"Expert Opin. Drug Discovery"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0155","doi-asserted-by":"crossref","first-page":"35018","DOI":"10.1038\/s41598-025-20712-4","article-title":"Antiproliferation, 3D-multicellular spheroid and VEGFR-2 inhibitory properties of spiroindolin-2-ones with phosphonate function","volume":"15","author":"Hassan","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110313_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109278","article-title":"Design, synthesis, and anticancer evaluation of spirooxindole\u20131,2,3-triazole hybrids as potent VEGFR-2 inhibitors","volume":"167","author":"Barakat","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0165","series-title":"Novel 3-Spiroindolin-2-One Derivatives as Cell Cycle Modulators: Design, Synthesis, Anticancer Evaluation, and Molecular Modeling Studies","author":"Sharkawy","year":"2025"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110313_bb0170","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1007\/s00044-016-1658-z","article-title":"Strategic synthesis and in vitro antimicrobial evaluation of novel difluoromethylated 1-(1, 3-diphenyl-1H-pyrazol-4-yl)-3, 3-difluoro-1, 3-dihydro-indol-2-ones","volume":"25","author":"Chundawat","year":"2016","journal-title":"Med. Chem. Res."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110313_bb0175","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202400662","article-title":"Third-generation CD73 inhibitors based on a 4,6-disubstituted-2-thiopyridine scaffold","volume":"20","author":"Grosjean","year":"2025","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bioorg.2026.110313_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.saa.2020.118056","article-title":"One-pot synthesis of thiazolo[3,2-a]pyrimidine derivatives, their cytotoxic evaluation and molecular docking studies","volume":"231","author":"Sekhar","year":"2020","journal-title":"Spectrochim. Acta A Mol. Biomol. Spectrosc."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110313_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26020412","article-title":"A new CDK2 inhibitor with 3-Hydrazonoindolin-2-one scaffold endowed with anti-breast Cancer activity: design, synthesis, biological evaluation, and in silico insights","volume":"26","author":"Al-Sanea","year":"2021","journal-title":"Molecules"},{"issue":"42","key":"10.1016\/j.bioorg.2026.110313_bb0190","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.2174\/0929867325666180904115000","article-title":"Advances in docking","volume":"26","author":"Sulimov","year":"2019","journal-title":"Curr. Med. Chem."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110313_bb0195","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075992","article-title":"Ligand pose and orientational sampling in molecular docking","volume":"8","author":"Coleman","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.110313_bb0200","series-title":"Amber 2022","author":"Case","year":"2022"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110313_bb0205","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1021\/ct400314y","article-title":"Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald","volume":"9","author":"Salomon-Ferrer","year":"2013","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110313_bb0210","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1021\/ct100578z","article-title":"PROPKA3: consistent treatment of internal and surface residues in empirical pKa predictions","volume":"7","author":"Olsson","year":"2011","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"8","key":"10.1016\/j.bioorg.2026.110313_bb0215","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110313_bb0220","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0225","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/1096-987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F","article-title":"How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules?","volume":"21","author":"Wang","year":"2000","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0230","series-title":"Gaussian 09, revision E.01","author":"Frisch","year":"2009"},{"issue":"2","key":"10.1016\/j.bioorg.2026.110313_bb0235","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"issue":"20","key":"10.1016\/j.bioorg.2026.110313_bb0240","doi-asserted-by":"crossref","first-page":"6183","DOI":"10.1021\/acs.jcim.3c01153","article-title":"AmberTools","volume":"63","author":"Case","year":"2023","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0245","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: An N\u00b7log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"issue":"3","key":"10.1016\/j.bioorg.2026.110313_bb0250","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0021-9991(77)90098-5","article-title":"Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes","volume":"23","author":"Ryckaert","year":"1977","journal-title":"J. Comput. Phys."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110313_bb0255","doi-asserted-by":"crossref","first-page":"3084","DOI":"10.1021\/ct400341p","article-title":"PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data","volume":"9","author":"Roe","year":"2013","journal-title":"J. Chem. Theor. Comput."},{"issue":"16","key":"10.1016\/j.bioorg.2026.110313_bb0260","doi-asserted-by":"crossref","first-page":"9478","DOI":"10.1021\/acs.chemrev.9b00055","article-title":"End-point binding free energy calculation with MM\/PBSA and MM\/GBSA: strategies and applications in drug design","volume":"119","author":"Wang","year":"2019","journal-title":"Chem. Rev."},{"issue":"5","key":"10.1016\/j.bioorg.2026.110313_bb0265","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","article-title":"The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities","volume":"10","author":"Genheden","year":"2015","journal-title":"Expert Opin. Drug Discovery"},{"issue":"9","key":"10.1016\/j.bioorg.2026.110313_bb0270","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA.Py: An efficient program for end-state free energy calculations","volume":"8","author":"Miller","year":"2012","journal-title":"Journal of Chemical Theory and Computation"},{"issue":"16","key":"10.1016\/j.bioorg.2026.110313_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26164908","article-title":"Synthesis of novel N-Acylhydrazones and their C-N\/N-N bond conformational characterization by NMR spectroscopy","volume":"26","author":"Munir","year":"2021","journal-title":"Molecules"},{"issue":"19","key":"10.1016\/j.bioorg.2026.110313_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914739","article-title":"New insights into Acylhydrazones E\/Z isomerization: An experimental and theoretical approach","volume":"24","author":"Fern\u00e1ndez-Palacios","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.bioorg.2026.110313_bb0285","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1007\/s00044-017-1939-1","article-title":"Design, synthesis, 3D pharmacophore, QSAR, and docking studies of some new (6-methoxy-2-naphthyl) propanamide derivatives with expected anti-bacterial activity as FABI inhibitor","volume":"26","author":"Eissa","year":"2017","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2026.110313_bb0290","article-title":"Synthesis and biological assessment of novel acylhydrazone derivatives of 2-methyl-1,4-naphthoquinone","volume":"10","author":"Atallah","year":"2017","journal-title":"Org. Commun."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0295","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3233\/CH-199226","article-title":"NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies","volume":"73","author":"Schulz","year":"2019","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"10.1016\/j.bioorg.2026.110313_bb0300","article-title":"Discovery of new VEGFR-2 inhibitors: design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies","volume":"27","author":"Elkaeed","year":"2022","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0305","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1080\/14756366.2022.2110868","article-title":"Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies","volume":"37","author":"Yousef","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0310","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ejmech.2016.12.007","article-title":"Synthesis and antiproliferative activity of monocationic arylthiophene derivatives","volume":"126","author":"Ismail","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/cells14161299","article-title":"Selective anticancer activity and safety profile of Chlorochalcones: impact on breast cancer, blood, and endothelial cells","volume":"14","author":"Cyboran-Miko\u0142ajczyk","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110313_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2022.969559","article-title":"Study of the anticancer effect of new quinazolinone hydrazine derivatives as receptor tyrosine kinase inhibitors","volume":"10","author":"Mortazavi","year":"2022","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2026.110313_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138012","article-title":"Hydrazide-hydrazone\/hydrazone as enabling linkers in anti-cancer drug discovery: a comprehensive review","volume":"1307","author":"Murugappan","year":"2024","journal-title":"J. Mol. Struct."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0330","doi-asserted-by":"crossref","DOI":"10.3390\/biom10010138","article-title":"A review of the structure-activity relationship of natural and synthetic Antimetastatic compounds","volume":"10","author":"Liew","year":"2020","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110313_bb0335","doi-asserted-by":"crossref","first-page":"4186","DOI":"10.1021\/acsomega.3c04749","article-title":"Structure-activity relationship study and design strategies of Hydantoin, thiazolidinedione, and Rhodanine-based kinase inhibitors: a two-decade review","volume":"9","author":"Naufal","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110313_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.109066","article-title":"Design, synthesis, and computational validation of novel benzothiazole derivatives as dual anticancer-antioxidant agents targeting VEGFR-2","volume":"166","author":"Mohamed","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2026.110313_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202100706","article-title":"Styryl group, a friend or foe in medicinal chemistry","volume":"17","author":"Bhurta","year":"2022","journal-title":"ChemMedChem"},{"issue":"28","key":"10.1016\/j.bioorg.2026.110313_bb0350","doi-asserted-by":"crossref","first-page":"24838","DOI":"10.1021\/acsomega.2c03047","article-title":"Substituent-controlled structural, supramolecular, and cytotoxic properties of a series of 2-Styryl-8-nitro and 2-Styryl-8-hydroxy Quinolines","volume":"7","author":"Sehlangia","year":"2022","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2026.110313_bb0355","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1476-4598-8-118","article-title":"Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1\/2, MCL-1 and ezrin pathways","volume":"8","author":"Pignochino","year":"2009","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.bioorg.2026.110313_bb0360","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0365","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-026-41232-9","article-title":"AI fragmentation-based optimization of Sorafenib derivatives targeting VEGFR2 for angiogenesis-related pathologies: a structure-based in-silico study","volume":"16","author":"Inan","year":"2026","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0370","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1080\/14756366.2021.1901089","article-title":"Design, synthesis, anticancer evaluation, and molecular modelling studies of novel tolmetin derivatives as potential VEGFR-2 inhibitors and apoptosis inducers","volume":"36","author":"Kassab","year":"2021","journal-title":"J. Enzyme Inhib. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110313_bb0375","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmr.2024.100030","article-title":"Cell cycle dysregulation in cancer","volume":"77","author":"Glaviano","year":"2025","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bioorg.2026.110313_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27073018","article-title":"From synthesis to mechanism: biological evaluation of a p-toluidine-based thiazolidinone-quinoline VEGFR-2 candidate supported by CADD","volume":"27","author":"Manni","year":"2026","journal-title":"Int. J. Mol. Sci."},{"issue":"24","key":"10.1016\/j.bioorg.2026.110313_bb0385","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245944","article-title":"Antiproliferative and antiangiogenic properties of new VEGFR-2-targeting 2-thioxobenzo[g]quinazoline derivatives (in vitro)","volume":"25","author":"Abuelizz","year":"2020","journal-title":"Molecules"},{"issue":"7","key":"10.1016\/j.bioorg.2026.110313_bb0390","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.4103\/jcrt.jcrt_308_22","article-title":"Induction of G0\/G1 phase cell cycle arrest and apoptosis by thymol through ROS generation and caspase-9\/\u22123 activation in breast and colorectal cancer cell lines","volume":"19","author":"Anvarbatcha","year":"2023","journal-title":"J. Cancer Res. Ther."},{"issue":"48","key":"10.1016\/j.bioorg.2026.110313_bb0395","first-page":"58943","article-title":"Development of the 5-Nitrosalicaldehyde Arylhydrazones as anticancer (MCF-7 and HCT116) agents targeting inhibition of VEGFR-2 and cytokines (IL-6 and TNF-\u03b1)","volume":"10","author":"Nkoana","year":"2025","journal-title":"ACS Omega"},{"issue":"50","key":"10.1016\/j.bioorg.2026.110313_bb0400","doi-asserted-by":"crossref","first-page":"82820","DOI":"10.18632\/oncotarget.12652","article-title":"Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling","volume":"7","author":"Zhou","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bioorg.2026.110313_bb0405","doi-asserted-by":"crossref","first-page":"603","DOI":"10.18632\/aging.100934","article-title":"Apoptosis as anticancer mechanism: function and dysfunction of its modulators and targeted therapeutic strategies","volume":"8","author":"Pistritto","year":"2016","journal-title":"Aging (Albany NY)"},{"issue":"15","key":"10.1016\/j.bioorg.2026.110313_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27155047","article-title":"Modified Benzoxazole-based VEGFR-2 inhibitors and apoptosis inducers: design, synthesis, and anti-proliferative evaluation","volume":"27","author":"Elwan","year":"2022","journal-title":"Molecules"},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0415","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1101\/gad.13.12.1501","article-title":"CDK inhibitors: positive and negative regulators of G1-phase progression","volume":"13","author":"Sherr","year":"1999","journal-title":"Genes Dev."},{"issue":"11","key":"10.1016\/j.bioorg.2026.110313_bb0420","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.tcb.2018.07.002","article-title":"CDK4\/6 inhibition in Cancer: beyond cell cycle arrest","volume":"28","author":"Goel","year":"2018","journal-title":"Trends Cell Biol."},{"issue":"2","key":"10.1016\/j.bioorg.2026.110313_bb0425","doi-asserted-by":"crossref","DOI":"10.3892\/ijmm.2025.5564","article-title":"The regulatory role of CDK4\/6 inhibitors in tumor immunity and the potential value of tumor immunotherapy (review)","volume":"56","author":"He","year":"2025","journal-title":"Int. J. Mol. Med."},{"issue":"6","key":"10.1016\/j.bioorg.2026.110313_bb0430","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.21037\/tcr-22-2807","article-title":"A narrative review about CDK4\/6 inhibitors in the setting of drug resistance: updates on biomarkers and therapeutic strategies in breast cancer","volume":"12","author":"Zhao","year":"2023","journal-title":"Transl. Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0435","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12906-016-1364-x","article-title":"Anti-cancer activity of Psoralea fructus through the downregulation of cyclin D1 and CDK4 in human colorectal cancer cells","volume":"16","author":"Park","year":"2016","journal-title":"BMC Complement. Altern. Med."},{"issue":"12","key":"10.1016\/j.bioorg.2026.110313_bb0440","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123327","article-title":"Regulation of cell cycle progression by growth factor-induced cell signaling","volume":"10","author":"Wang","year":"2021","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.bioorg.2026.110313_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/ijms27031228","article-title":"Cyclin D1\/D2-CDK4 drives cell migration by orchestrating cytoskeletal dynamics through a TGF\u03b2-FAK-Rac1 axis","volume":"27","author":"Guo","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110313_bb0450","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ejmech.2019.02.050","article-title":"Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors","volume":"168","author":"Zeidan","year":"2019","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2026.110313_bb0455","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272362","article-title":"Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway","volume":"17","author":"Taghour","year":"2022","journal-title":"PloS One"},{"key":"10.1016\/j.bioorg.2026.110313_bb0460","unstructured":"Bank, P.D. Crystal Structure of VEGFR2 in Complex with SORAFENIB. [cited 2025; Available from: https:\/\/www.rcsb.org\/structure\/4ASD."},{"key":"10.1016\/j.bioorg.2026.110313_bb0465","unstructured":"Chemical Computing Group, U.L.C, Molecular Operating Environment (MOE), 2020.01. 2025: Montreal, QC, Canada."},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0470","doi-asserted-by":"crossref","DOI":"10.1007\/s44371-025-00173-4","article-title":"2D-QSAR driven design, molecular docking, molecular dynamics simulation and MM\/GBSA studies on quinazoline derivatives for development of VEGFR-2 inhibitors","volume":"2","author":"Kashyap","year":"2025","journal-title":"Discover Chemistry"},{"issue":"1","key":"10.1016\/j.bioorg.2026.110313_bb0475","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8321400","article-title":"Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: design, synthesis, and biological evaluation","volume":"2021","author":"Ran","year":"2021","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2026.110313_bb0480","unstructured":"SwissADME. [Accessed at January 25,. 2026]; Available from: http:\/\/www.swissadme.ch\/."},{"key":"10.1016\/j.bioorg.2026.110313_bb0485","unstructured":"pkCSM. [Accessed at January 20,. 2026]; Available from: http:\/\/biosig.unimelb.edu.au\/pkcsm\/prediction."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008497?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826008497?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:03:29Z","timestamp":1791407009000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826008497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":97,"alternative-id":["S0045206826008497"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110313","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ligand-based design and synthesis of novel 3-spiro-2-oxindoline derivatives as potent VEGFR-2 inhibitors with antiproliferative activity and cell cycle arrest","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110313","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110313"}}